- Home
- EXEL vs BAX Comparison
EXEL vs BAX Comparison
Compare EXEL & BAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXEL | BAX |
|---|---|---|
| Founded | 1994 | 1931 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 10.2B |
| IPO Year | 2000 | 1994 |
Fundamental Metrics
Financial Performance| Metric | EXEL | BAX |
|---|---|---|
| Price | $50.03 | $19.22 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 21 | 9 |
| Target Price | ★ $46.50 | $21.00 |
| AVG Volume (30 Days) | 2.6M | ★ 7.4M |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 0.24% |
| EPS Growth | ★ 57.95 | N/A |
| EPS | ★ 0.79 | N/A |
| Revenue | $452,477,000.00 | ★ $11,244,000,000.00 |
| Revenue This Year | $13.61 | $1.96 |
| Revenue Next Year | $13.13 | $2.22 |
| P/E Ratio | $62.76 | ★ N/A |
| Revenue Growth | N/A | ★ 5.72 |
| 52 Week Low | $33.76 | $15.73 |
| 52 Week High | $51.63 | $32.04 |
Technical Indicators
Market Signals| Indicator | EXEL | BAX |
|---|---|---|
| Relative Strength Index (RSI) | 60.47 | 62.31 |
| Support Level | $40.42 | $18.95 |
| Resistance Level | $51.63 | $19.82 |
| Average True Range (ATR) | 1.67 | 0.63 |
| MACD | 0.06 | 0.20 |
| Stochastic Oscillator | 79.07 | 85.13 |
Price Performance
Historical ComparisonAbout EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About BAX Baxter International Inc.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.